Open AccessFocused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
Author(s) -
Hanfei Guo,
Lei Qian,
Jiuwei Cui
Publication year - 2021
Publication title -
cancer biology and medicine
Language(s) - English
Resource type - Journals
ISSN - 2095-3941
DOI - 10.20892/j.issn.2095-3941.2021.0087
Subject(s) - cytokine release syndrome , chimeric antigen receptor , immunology , cytokine , medicine , pathogenesis , receptor , antigen , macrophage , immunotherapy , myeloid cells , myeloid , biology , immune system , biochemistry , in vitro
Cytokine release syndrome (CRS) is a major obstacle to the widespread clinical application of chimeric antigen receptor (CAR) T cell therapies. CRS can also be induced by infections (such as SARS-CoV-2), drugs (such as therapeutic antibodies), and some autoimmune diseases. Myeloid-derived macrophages play key roles in the pathogenesis of CRS, and participate in the production and release of the core CRS cytokines, including interleukin (IL)-1, IL-6, and interferon-γ. In this review, we summarize the roles of macrophages in CRS and discuss new developments in macrophage activation and the related mechanisms of cytokine regulation in CRS.